AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)
Post# of 61
(Total Views: 273)
Posted On: 09/08/2021 4:45:59 PM
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment
- AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021
- The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China
- A recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world and 1st in China for the number of clinical samples analyzed amongst companies that offer next-generation early cancer screening and detection technology
AnPac Bio-Medical Science (NASDAQ: ANPC) recently held its 2021 technical symposium entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment.” The symposium was held in Shanghai, China, and was attended by life science Fortune 500 companies such as Thermo Fisher Scientific and Roche Pharmaceuticals.
Experts came together to discuss emerging cancer prevention and treatment theories and technologies, including the applications of biophysical technology to address these needs. Measurement of biophysical properties is the basis for Anpac Bio’s novel CDA technology. The Company’s CDA technology can rapidly detect 26 different types of cancers with a simple blood test.
Talking points of the symposium included the newly announced cooperation between AnPac Bio and Roche Pharmaceutical China, as well as Thermo Fisher Scientific’s latest developments in in-vitro diagnosis (“IVD”), and the clinical trials that have been held on AnPac Bio’s proprietary cancer differentiation analysis (“CDA”) technology, including recently unblinded and analyzed clinical data.
AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter, and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical properties and has achieved significant results. In 2019, Frost & Sullivan ranked AnPac Bio third in the world and first in China among those companies in the region in terms of the number of clinical samples offering next-generation early cancer screening and detection.
With one of the largest sample libraries in the world and more than 220,000 samples tested, AnPac Bio is an innovative leader in the field. The company’s CDA technology has shown to be advantageous over traditional detection methods, allowing it to outperform in the early detection market. The company’s main goal for 2021 is to extend its major discoveries in the field of early cancer detection and also develop cancer treatment technologies.
“This technical symposium allowed people to better understand the most cutting-edge applications of biophysical technology in cancer prevention and treatment, and it also played an important role in promoting future research and development in cancer prevention and treatment,” Dr. Chris Yu, CEO and Chairman of AnPac Bio, said. “As a pioneer in the application of biophysics to cancer prevention and treatment, AnPac Bio continues to report new ideas and cutting-edge technology to the public, sharing the latest clinical study and trial results, and continuing to promote collaborations between industry, and academia.”
AnPac Bio has proven to be an early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. The company’s patent applications and IP began in the early 2010’s, and by 2014 it had already announced a cancer screening product with the capability of screening 16 types of cancer earlier than anyone else in the industry.
AnPac Bio’s CDA technology combines the assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead up to serious health conditions (including cancer). The technology can also be used to pinpoint the most likely location for cancer or predict where the risk will be high in the future. Having invented and championed the idea and method of “multi-level, multi-parameter” cancer screening, AnPac Bio’s contributions are now recognized and accepted by leading United States medical institutions and life science companies.
For more information, visit the company’s website at www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://nnw.fm/ANPC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021
- The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China
- A recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world and 1st in China for the number of clinical samples analyzed amongst companies that offer next-generation early cancer screening and detection technology
AnPac Bio-Medical Science (NASDAQ: ANPC) recently held its 2021 technical symposium entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment.” The symposium was held in Shanghai, China, and was attended by life science Fortune 500 companies such as Thermo Fisher Scientific and Roche Pharmaceuticals.
Experts came together to discuss emerging cancer prevention and treatment theories and technologies, including the applications of biophysical technology to address these needs. Measurement of biophysical properties is the basis for Anpac Bio’s novel CDA technology. The Company’s CDA technology can rapidly detect 26 different types of cancers with a simple blood test.
Talking points of the symposium included the newly announced cooperation between AnPac Bio and Roche Pharmaceutical China, as well as Thermo Fisher Scientific’s latest developments in in-vitro diagnosis (“IVD”), and the clinical trials that have been held on AnPac Bio’s proprietary cancer differentiation analysis (“CDA”) technology, including recently unblinded and analyzed clinical data.
AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter, and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical properties and has achieved significant results. In 2019, Frost & Sullivan ranked AnPac Bio third in the world and first in China among those companies in the region in terms of the number of clinical samples offering next-generation early cancer screening and detection.
With one of the largest sample libraries in the world and more than 220,000 samples tested, AnPac Bio is an innovative leader in the field. The company’s CDA technology has shown to be advantageous over traditional detection methods, allowing it to outperform in the early detection market. The company’s main goal for 2021 is to extend its major discoveries in the field of early cancer detection and also develop cancer treatment technologies.
“This technical symposium allowed people to better understand the most cutting-edge applications of biophysical technology in cancer prevention and treatment, and it also played an important role in promoting future research and development in cancer prevention and treatment,” Dr. Chris Yu, CEO and Chairman of AnPac Bio, said. “As a pioneer in the application of biophysics to cancer prevention and treatment, AnPac Bio continues to report new ideas and cutting-edge technology to the public, sharing the latest clinical study and trial results, and continuing to promote collaborations between industry, and academia.”
AnPac Bio has proven to be an early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. The company’s patent applications and IP began in the early 2010’s, and by 2014 it had already announced a cancer screening product with the capability of screening 16 types of cancer earlier than anyone else in the industry.
AnPac Bio’s CDA technology combines the assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead up to serious health conditions (including cancer). The technology can also be used to pinpoint the most likely location for cancer or predict where the risk will be high in the future. Having invented and championed the idea and method of “multi-level, multi-parameter” cancer screening, AnPac Bio’s contributions are now recognized and accepted by leading United States medical institutions and life science companies.
For more information, visit the company’s website at www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://nnw.fm/ANPC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)AnPac Bio-Medical Science Co. Ltd. (ANPC) Stock Research Links
Scroll down for more posts ▼